Avacta (LSE:AVCT) reported continued progress across its oncology pipeline during 2025, advancing multiple generations of its proprietary pre|CISION platform. The company said AVA6000 and AVA6103 are now in clinical development, while AVA6207 continues to advance through preclinical dual-payload studies.
Management highlighted encouraging efficacy and cardiac safety data from AVA6000, alongside the launch of the FOCUS 01 Phase 1 trial for AVA6103, which is targeting six advanced cancer indications. The company also reported ongoing expansion of its intellectual property portfolio, particularly around sustained-release and dual-payload delivery technologies.
Avacta strengthened its management team during the year with several appointments across finance, scientific and medical leadership roles. The group also reinforced its financial position through £32.5 million of equity fundraising and revised terms on its convertible bonds, extending its projected cash runway into early 2027.
The company expects important clinical data updates from both AVA6000 and AVA6103 during 2026. Management also confirmed that discussions regarding potential partnership agreements are ongoing, with such deals potentially providing non-dilutive financing opportunities and supporting wider use of the platform across additional oncology applications.
Despite progress in development programmes, the company’s broader outlook remains weighed down by weak financial performance and negative technical indicators. Continued funding requirements and the absence of major commercial partnerships remain key risks. Valuation also appears unattractive given ongoing losses and the lack of dividend support.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biopharmaceutical company focused on oncology therapies. Its proprietary pre|CISION peptide drug conjugate platform is designed to deliver highly potent cancer treatments directly to tumours by targeting fibroblast activation protein within the tumour microenvironment, aiming to improve efficacy while reducing systemic toxicity.
Leave a Reply